RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/12379450http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/12379450http://www.w3.org/2000/01/rdf-schema#comment"Glycogen synthase kinase-3 (GSK-3) is a highly conserved serine/threonine protein kinase that is involved in the signal transduction cascades of multiple cellular processes. GSK-3 has two isoforms, designated alpha and beta. GSK-3beta protein levels and GSK-3 enzyme activity have been reported to be reduced by over 40% in postmortem frontal cortex of schizophrenic patients. GSK-3 is also present in peripheral tissue such as lymphocytes. In this study we aimed to find whether the reduction in brain GSK-3beta measures is reflected in peripheral tissue of schizophrenic patients. Fresh lymphocytes from schizophrenic patients showed no difference in GSK-3 alpha and GSK-3beta mRNA levels, GSK-3beta protein levels, or total GSK-3 (alpha+beta) enzyme activity compared with findings in control subjects. In addition, lymphocyte-derived cell lines from schizophrenic patients did not differ in their GSK-3beta protein levels from levels in normal control subjects. The results rule out the use of lymphocyte GSK-3 as a marker for central GSK-3 abnormalities in schizophrenia."xsd:string
http://purl.uniprot.org/citations/12379450http://purl.org/dc/terms/identifier"doi:10.1016/s0165-1781(02)00191-9"xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/author"Agam G."xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/author"Bersudsky Y."xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/author"Kozlovsky N."xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/author"Nadri C."xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/date"2002"xsd:gYear
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/name"Psychiatry Res"xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/pages"51-57"xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/title"GSK-3 parameters in lymphocytes of schizophrenic patients."xsd:string
http://purl.uniprot.org/citations/12379450http://purl.uniprot.org/core/volume"112"xsd:string
http://purl.uniprot.org/citations/12379450http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/12379450
http://purl.uniprot.org/citations/12379450http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/12379450
http://purl.uniprot.org/uniprot/#_A0A3B3ITW1-mappedCitation-12379450http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/#_B5BUC0-mappedCitation-12379450http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/#_P49841-mappedCitation-12379450http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/#_Q86TM2-mappedCitation-12379450http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/#_Q6FI27-mappedCitation-12379450http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/P49841http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/Q6FI27http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/B5BUC0http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/Q86TM2http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/12379450
http://purl.uniprot.org/uniprot/A0A3B3ITW1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/12379450